Citation only
via OpenAlex
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection
Sahil Khanna, Darrell S. Pardi, Colleen R. Kelly, Colleen S. Kraft, Tanvi Dhere, Matthew R. Henn, Mary-Jane Lombardo, Marin Vulić, Toshiro K. Ohsumi, Jonathan A. Winkler, Christina Pindar, Barbara McGovern, Roger J. Pomerantz, John G Aunins, David N. Cook
The Journal of Infectious Diseases · 2016 · ▲ 328 citations
Abstract
BACKGROUND: Patients with recurrent Clostridium difficile infection (CDI) have a ≥60% risk of relapse, as conventional therapies do not address the underlying gastrointestinal dysbiosis. This exploratory study evaluated the safety and efficacy of bacterial spores for preventing recurrent CDI. METHODS: Stool specimens from healthy donors were treated with ethanol to eliminate pathogens. The resulting spores were fractionated and encapsulated for oral delivery as SER-109. Following their response to standard-of-care antibiotics, patients in cohort 1 were treated with SER-109 on 2 consecutive days (geometric mean dose, 1.7 × 10(9) spores), and those in cohort 2 were treated on 1 day (geometric mean dose, 1.1 × 10(8) spores). The primary efficacy end point was absence of C. difficile-positive diarrhea during an 8-week follow-up period. Microbiome alterations were assessed. RESULTS: Thirty patients (median age, 66.5 years; 67% female) were enrolled, and 26 (86.7%) met the primary efficacy end point. Three patients with early, self-limiting C. difficile-positive diarrhea did not require antibiotics and tested negative for C. difficile at 8 weeks; thus, 96.7% (29 of 30) achieved clinical resolution. In parallel, gut microbiota rapidly diversified, with durable engraftment of spores and no outgrowth of non-spore-forming bacteria found after SER-109 treatment. Adverse events included mild diarrhea, abdominal pain, and nausea. CONCLUSIONS: SER-109 successfully prevented CDI and had a favorable safety profile, supporting a novel microbiome-based intervention as a potential therapy for recurrent CDI.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/infdis/jiv766
- Canonical
- link ↗
- Fetched
- 2026-10-02 MST
Cite this
APA
Khanna, S., Pardi, D.S., Kelly, C.R., Kraft, C.S., Dhere, T., Henn, M.R., Lombardo, M., Vulić, M., Ohsumi, T.K., Winkler, J.A., Pindar, C., McGovern, B., Pomerantz, R.J., Aunins, J.G., Cook, D.N., & Hohmann, E.L. (2016). A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection. <em>The Journal of Infectious Diseases</em>. https://doi.org/10.1093/infdis/jiv766
Vancouver
Khanna S, Pardi DS, Kelly CR, Kraft CS, Dhere T, Henn MR, et al. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection. The Journal of Infectious Diseases. 2016. doi:10.1093/infdis/jiv766.
BibTeX
@article{sahil2016ANovel,
title = {A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection},
author = {Sahil Khanna and Darrell S. Pardi and Colleen R. Kelly and Colleen S. Kraft and Tanvi Dhere and Matthew R. Henn and Mary-Jane Lombardo and Marin Vulić and Toshiro K. Ohsumi and Jonathan A. Winkler and Christina Pindar and Barbara McGovern and Roger J. Pomerantz and John G Aunins and David N. Cook and Elizabeth L. Hohmann},
journal = {The Journal of Infectious Diseases},
year = {2016},
doi = {10.1093/infdis/jiv766},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Microbiology 2018
Open access · CC-BY
The Human Gut Microbiome – A Potential Controller of Wellness and Disease
Progress in molecular biology and translational science 2022
Citation only
Gut microbiome dysbiosis in neonatal sepsis
Scientific Reports 2017
Open access · CC-BY
Dysbiosis of the microbiome in gastric carcinogenesis
International Journal of Environmental Research and Public Health 2019
Open access · CC-BY
Exploring Epigenetic Age in Response to Intensive Relaxing Training: A Pilot Study to Slow Down Biological Age
Outlook Therapeutics, Inc. 2024
Open access · US-GOV
Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT
Paediatrica Indonesiana 2025
Open access · CC-BY